Previous Close | 12.32 |
Open | 12.54 |
Bid | 12.50 x 900 |
Ask | 14.70 x 1000 |
Day's Range | 12.19 - 13.24 |
52 Week Range | 7.55 - 40.64 |
Volume | |
Avg. Volume | 3,219,372 |
Market Cap | 637.969M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.82 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 46.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for NKTX
A look at the shareholders of Nkarta, Inc. ( NASDAQ:NKTX ) can tell us which group is most powerful. Large companies...
The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference: Cowen 3rd Annual Oncology Innovation SummitJune 2, 202211:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on t